• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有BRCA2基因新型变异的同步性卵巢癌和乳腺癌:一例报告

Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.

作者信息

Llinás-Quintero Néstor, Cabrera-Florez Eduardo, Mendoza-Fandiño Gustavo, Matute-Turizo Gustavo, Vasquez-Trespalacios Elsa M, Gallón-Villegas Luis J

机构信息

Breast Surgery Fellowship Program, School of Medicine, CES University, Medellín, Colombia.

School of Medicine, CES University, Medellín, Colombia.

出版信息

Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.

DOI:10.1155/2019/6958952
PMID:30723561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6339711/
Abstract

We report a case of a 52-year-old female with a family history of pancreatic and colon cancers who presented with a right breast mass positive for high-grade medullar carcinoma with triple-negative biomolecular profile. Further workup was performed finding a left ovarian mass. The patient underwent laparotomy performing optimal cytoreduction on bilateral ovarian tumors; the pathology and immunohistochemistry confirmed bilateral ovary adenocarcinoma with positive peritoneal malignancy. Due to her synchronic breast and ovarian cancers, a genetic profile was performed detecting a new pathogenic variant in the BRCA2 gene: c.3606_3607del (p.Ser1203Cysfs). She was given chemotherapy with carboplatin and paclitaxel obtaining complete clinical response. Regarding her breast cancer, she had a right modified radical mastectomy and prophylactic left mastectomy obtaining complete clinical response. This case presents with an unusual subtype and difficult histologic diagnosis of a synchronic medullar breast cancer and ovary carcinoma associated with a new mutation of the BRCA2 gene.

摘要

我们报告一例52岁女性,有胰腺癌和结肠癌家族史,因右乳肿块就诊,该肿块经检查为高级别髓样癌,具有三阴性生物分子特征。进一步检查发现左侧卵巢有肿块。患者接受剖腹手术,对双侧卵巢肿瘤进行了最佳细胞减灭术;病理和免疫组化证实为双侧卵巢腺癌伴腹膜恶性肿瘤阳性。由于她同时患有乳腺癌和卵巢癌,进行了基因检测,发现BRCA2基因有一个新的致病变异:c.3606_3607del(p.Ser1203Cysfs)。她接受了卡铂和紫杉醇化疗,获得了完全临床缓解。关于她的乳腺癌,她接受了右改良根治性乳房切除术和预防性左乳房切除术,也获得了完全临床缓解。该病例呈现出一种不寻常的亚型,同步性髓样乳腺癌和卵巢癌的组织学诊断困难,且与BRCA2基因的新突变有关。

相似文献

1
Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.伴有BRCA2基因新型变异的同步性卵巢癌和乳腺癌:一例报告
Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.
2
[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].[BRCA1 突变携带者中的多原发性恶性肿瘤——两例临床病例]
Ginekol Pol. 2013 Oct;84(10):892-6. doi: 10.17772/gp/1657.
3
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.预防性卵巢切除术:降低美国上皮性卵巢癌死亡率。一场持续的争论。
Oncologist. 1996;1(5):326-330.
4
An interesting case of likely related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube.一例可能相关的双侧乳腺癌伴输卵管伞端转移的有趣病例。
Hered Cancer Clin Pract. 2020 Mar 19;18:7. doi: 10.1186/s13053-020-00139-w. eCollection 2020.
5
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.BRCA 突变携带者的双侧预防性乳房切除术:外科医生需要了解的内容。
Ann Ital Chir. 2019;90:1-2.
6
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.接受BRCA1和BRCA2检测的女性临床特征与风险降低干预措施之间的关联:一项单机构研究。
Cancer. 2006 Dec 15;107(12):2745-51. doi: 10.1002/cncr.22352.
7
Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer.HER2阳性转移性乳腺癌女性的当前及新出现的治疗方法
J Adv Pract Oncol. 2017 Mar;8(2):164-168. Epub 2017 Mar 1.
8
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.在三阴性乳腺癌(BrighTNess)中,将 PARP 抑制剂 veliparib 联合卡铂或卡铂单药添加到标准新辅助化疗中:一项随机、3 期试验。
Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28.
9
A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.BRCA1基因突变风险降低手术后的诊断困境——一例表现为乙状结肠癌的原发性乳头状浆液性癌病例报告
World J Surg Oncol. 2007 Sep 12;5:102. doi: 10.1186/1477-7819-5-102.
10
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.遗传性乳腺癌患者乳腺实质的病理特征,包括BRCA1和BRCA2突变携带者。
Cancer. 2003 Jan 1;97(1):1-11. doi: 10.1002/cncr.11048.

引用本文的文献

1
A case of simultaneous breast cancer and ovarian cancer based on a hereditary breast and ovarian cancer syndrome.遗传性乳腺癌和卵巢癌综合征相关的同时性乳腺癌和卵巢癌 1 例报告
Nagoya J Med Sci. 2023 Nov;85(4):814-821. doi: 10.18999/nagjms.85.4.814.
2
Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy.拉美乳腺癌中 DNA 修复基因种系突变的全景:PARP 抑制剂和免疫疗法的机会。
Genes (Basel). 2019 Oct 10;10(10):786. doi: 10.3390/genes10100786.

本文引用的文献

1
Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.乳腺髓样癌,一种与 BCLG 过表达相关的三阴性乳腺癌。
Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.
2
Medullary Breast Carcinoma and Invasive Ductal Carcinoma: A Review Study.髓样乳腺癌和浸润性导管癌:一项综述研究
Iran J Med Sci. 2018 Jul;43(4):365-371.
3
Clinical practice guidelines in breast cancer.乳腺癌临床实践指南
Curr Oncol. 2018 Jun;25(Suppl 1):S151-S160. doi: 10.3747/co.25.3729. Epub 2018 Jun 13.
4
Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.三阴性乳腺癌的组织学异质性:国家癌症中心数据库分析。
Eur J Cancer. 2018 Jul;98:48-58. doi: 10.1016/j.ejca.2018.04.011. Epub 2018 Jun 2.
5
The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer.三阴性乳腺癌不同组织学亚型的临床病理特征及生存结果
J Cancer. 2018 Jan 1;9(2):296-303. doi: 10.7150/jca.22280. eCollection 2018.
6
St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.2017年圣加仑/维也纳会议:原发性乳腺癌治疗强化与降阶梯共识讨论简述
Breast Care (Basel). 2017 May;12(2):102-107. doi: 10.1159/000475698. Epub 2017 Apr 26.
7
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.与表柔比星加紫杉醇相比,卡铂加紫杉醇作为局部晚期三阴性乳腺癌新辅助化疗的病理完全缓解和无复发生存情况更佳:一项随机2期试验。
Oncotarget. 2016 Sep 13;7(37):60647-60656. doi: 10.18632/oncotarget.10607.
8
Metastasis of ovarian cancer to the breast: A report of two cases and a review of the literature.卵巢癌转移至乳腺:两例报告并文献复习
Oncol Lett. 2016 Jun;11(6):4008-4012. doi: 10.3892/ol.2016.4514. Epub 2016 May 4.
9
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.新辅助卡铂联合多西他赛治疗三阴性乳腺癌的疗效:两个队列的联合分析
Clin Cancer Res. 2017 Feb 1;23(3):649-657. doi: 10.1158/1078-0432.CCR-16-0162. Epub 2016 Jun 14.
10
Translational and clinical research highlights from the 38th San Antonio Breast Cancer Symposium.第38届圣安东尼奥乳腺癌研讨会的转化研究与临床研究亮点
Future Oncol. 2016;12(8):1005-8. doi: 10.2217/fon-2016-0021. Epub 2016 Feb 9.